{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:03:42Z","timestamp":1762002222548,"version":"build-2065373602"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.eucr.2022.102278","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:58:03Z","timestamp":1667393883000},"page":"102278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report"],"prefix":"10.1016","volume":"45","author":[{"given":"Keita","family":"Ogasawara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Ikarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Tamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tsuyukubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Obara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eucr.2022.102278_bib1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eucr.2022.102278_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10147-021-02067-8","article-title":"Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN bladder 100 Japanese subgroup Analysis","volume":"27","author":"Tomita","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.eucr.2022.102278_bib3","article-title":"Hyperprogressive disease in malignant carcinoma with immune checkpoint inhibitor use: a review","volume":"9","author":"Liu","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.eucr.2022.102278_bib4","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/j.clgc.2019.09.009","article-title":"Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1\/PD-L1 inhibitors","volume":"18","author":"Hwang","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eucr.2022.102278_bib5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.4103\/apjon.apjon-2142","article-title":"Maintenance therapy with pembrolizumab after platinum-doublet chemotherapy leading to hyperprogression in a patient with metastatic bladder cancer","volume":"8","author":"Gu","year":"2021","journal-title":"Asia Pac J Oncol Nurs"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221444202200290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221444202200290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:57:25Z","timestamp":1762001845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221444202200290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":5,"alternative-id":["S221444202200290X"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2022.102278","relation":{},"ISSN":["2214-4420"],"issn-type":[{"type":"print","value":"2214-4420"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperprogressive disease after avelumab maintenance therapy in a patient with advanced ureter cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2022.102278","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102278"}}